Drugdiscovery >> Drugs >> News
5831
Views
Orphan Drug Designation for ReN003 retinal stem cell therapy - drugdiscovery.com
Orphan Drug Designation for ReN003 retinal stem cell therapy - drugdiscovery.com


ReNeuron Group’s ReN003 retinal stem cell therapy, candidate for retinitis pigmentosa, has been granted Orphan Drug Designation in both Europe and the U.S.
Read More >>


Tags: Orphan Drug Designation, ReN003, retinal stem cell therapy, retinitis pigmentosa, orphan drug, stem cell therapy - August 30, 2013
Related Articles
5111
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

7458
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

5713
Views
Breakthrough Therapy Designation for Firdapse Breakthrough Therapy Designation for Firdapse
FDA has granted a Breakthrough Therapy Designation to Catalyst Pharmaceutical Partners for the drug Firdapse (amifampridine phosphate), for the symptomatic treatment of patients with Lambert-Eaton Mya Read More >>

Tags: Firdapse, Lambert-Eaton Myasthenic Syndrome, LEMS, orphan drug, breakthrough therapy

15081
Views
Breakthrough therapy designation for Roche’s lung cancer drug alectinib Breakthrough therapy designation for Roche’s lung cancer drug alectinib
The FDA has granted breakthrough therapy designation for Roche’s promising investigational 2nd generation ALK inhibitor, used for the treatment of patients with metastatic non-small cell lung cance Read More >>

Tags: alectinib, lung cancer, breakthrough therapy designation, Roche, investigational drug, ALK inhibitor, metastatic non-small cell lung cancer, NSCLC, FDA

6512
Views
ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A ALN-AT3 gets a second Orphan Drug Designation, this time for Hemophilia A
After last week’s approval of Orphan Drug Designation to Alnylam Pharmaceuticals’ RNAi drug ALN-AT3 for the treatment of hemophilia B, this week it is for the treatment of hemophilia A . Read More >>

Tags: orphan, drug, ALN-AT3, Alnylam, RNAi, hemophilia

12994
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

2870
Views
Orphan Drug designation for SGX94 for acute radiation syndrome Orphan Drug designation for SGX94 for acute radiation syndrome
Soligenix’ innate defense regulator, SGX94, is a new class of short, synthetic peptides that accelerates resolution of tissue damage following exposure to a variety of agents including radiation, c Read More >>

Tags: orphan drug, SGX94, acute radiation syndrome, Soligenix, synthetic peptides

5261
Views
Breakthrough Therapy designation for leukemia drug Arzerra Breakthrough Therapy designation for leukemia drug Arzerra
The FDA has granted Breakthrough Therapy designation for the drug Arzerra (ofatumumab), co-development by Genamb and GSK, used in combination with chlorambucil for the treatment of patients with chro Read More >>

Tags: Arzerra, ofatumumab, chronic lymphocytic leukemia, CLL, breakthrough therapy designation

3160
Views
Breakthrough Therapy designation for AML drug volasertib Breakthrough Therapy designation for AML drug volasertib
The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim’s investigational compound - volasertib, for the treatment of patients with acute myeloid leukemia. Read More >>

Tags: volasertib, acute myeloid leukemia, Boehringer Ingelheim, breakthrough therapy,experimental drug

7926
Views
Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV
FDA has approved an Orphan Drug Designation to Advaxis’ next generation immunotherapy drug ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer. Read More >>

Tags: Advaxis, ADXS-HPV, HPV, anal cancer, human papillomavirus, immunotherapy, drug

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013